Ocular Therapeutix, Inc.
OCUL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.02 | -2.24 | -0.16 | -0.23 |
| FCF Yield | -2.64% | -3.53% | -3.75% | -2.76% |
| EV / EBITDA | -27.40 | -20.19 | -15.15 | -25.23 |
| Quality | ||||
| ROIC | -18.85% | -16.46% | -17.27% | -12.08% |
| Gross Margin | 87.80% | 85.56% | 88.13% | 92.80% |
| Cash Conversion Ratio | 0.73 | 0.81 | 0.70 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.13% | 1.24% | 4.89% | 7.36% |
| Free Cash Flow Growth | -0.42% | -21.20% | -17.59% | -8.14% |
| Safety | ||||
| Net Debt / EBITDA | 3.90 | 4.93 | 4.28 | 7.14 |
| Interest Coverage | 22.88 | -22.43 | -21.42 | -16.28 |
| Efficiency | ||||
| Inventory Turnover | 0.51 | 0.64 | 0.39 | 0.40 |
| Cash Conversion Cycle | 49.76 | 71.42 | 116.68 | 87.52 |